How Obstructive Sleep Apnea Treatment Is Evolving
Obstructive Sleep Apnea (OSA) is a common and serious sleep disorder characterized by repeated episodes of upper airway obstruction during sleep. Symptoms of OSA include loud snoring, excessive daytime sleepiness and observed episodes where you stop breathing during sleep. Understanding your individual risk factors is key to diagnosis and management.
OSA affects 1 in 5 adults and contributes to cardiovascular disease, metabolic dysfunction and poor quality of life. Untreated OSA is associated with serious health problems like cardiovascular disease and can reduce life expectancy. With the growth of precision medicine, digital health and behavioral interventions OSA care is moving from one size fits all to personalized approaches.
Polysomnography (PSG) is the gold standard for diagnosing OSA especially in complex or high risk cases [4] [6]. A sleep study is done in a sleep center and reviewed by a sleep specialist to ensure accurate diagnosis. As part of the assessment a healthcare provider will review your medical history and bedtime routine to evaluate risk factors and sleep patterns.
The diagnosis process involves identifying symptoms of obstructive sleep such as loud snoring, daytime sleepiness and witnessed apneas. There are different types of sleep apnea including obstructive sleep apnea and central sleep apnea. Obstructive apneas and breathing pauses are key findings during a sleep study while central sleep apnea is when the brain fails to send signals to breathing muscles resulting in central sleep disruptions. Something like this is different from other sleep-related issues such as narcolepsy and insomnia.
But recent updates support the growing role of home sleep apnea testing (HSAT), especially for patients with high pretest probability and fewer comorbidities [1] [3]. These tests get obstructive sleep apnea diagnosed. Portable devices now offer reliable data while improving access and reducing costs.
The 2015 systematic review also highlighted the emerging value of biomarkers—like IL-6 and kallikrein-1—as potential tools for assessing OSA severity [12].
Continuous Positive Airway Pressure (CPAP) is the foundation of OSA treatment especially in moderate to severe cases. Many studies have shown its effectiveness in reducing apnea events, improving sleep quality and lowering cardiovascular risk [1] [4] [5]. CPAP and other interventions keep the airway open and get sleep apnea treated.
But adherence is a major challenge. Alternatives like oral appliances, positional therapy and upper airway surgery are effective in milder cases or when CPAP is poorly tolerated [3] [6] [8]. Surgery may be necessary for patients with severe symptoms or when other therapies fail. Severe sleep apnea and severe OSA may require more aggressive or combination therapies.
Lifestyle changes like weight loss, exercise and alcohol/tobacco cessation are foundational interventions that should be part of any treatment plan [1] [3]. These lifestyle changes are key to managing mild sleep apnea and mild obstructive sleep apnea.
A comprehensive approach is often needed to get obstructive sleep apnea treated and to treat OSA.
Not all OSA cases are the same. Advances in phenotyping—the classification of patients by symptom clusters, anatomy and comorbidities—are shaping precision medicine approaches [7] [9]. This has led to new algorithms for selecting ideal therapies based on individual traits rather than a one size fits all CPAP prescription.
A 2025 phenotype-based study showed how different comorbidity profiles may predict which patients need early referral and treatment escalation [9].
The COVID-19 pandemic accelerated the adoption of telemedicine and sleep medicine was no exception. Virtual consultations, remote device monitoring and app-based interventions are being integrated into care. While current evidence is limited to consensus reports, early data suggests improved adherence and symptom tracking when digital tools are used [2].
Artificial intelligence (AI) and machine learning (ML) are being explored to streamline diagnosis, predict treatment outcomes and detect high-risk phenotypes [10]. A 2025 review noted the need for standardized datasets and validation models before widespread clinical use but the future looks promising.
Positional OSA, where apnea events occur primarily when lying on the back, has different cardiovascular outcomes and may respond to targeted interventions like positional therapy [14]. Airway obstruction in positional OSA occurs when the muscles in the back of the throat relax and the airway narrows and collapses.
Meanwhile drug-induced sleep endoscopy (DISE) in pediatric populations is gaining popularity as a tool to visualize dynamic airway collapse and guide surgical decision making [13]. Visualization during DISE often shows collapse at the level of the soft palate which guides surgical decisions.
OSA's role in metabolic disease, including type 2 diabetes, dyslipidemia, metabolic syndrome and diabetes mellitus is being uncovered [11]. Treating sleep apnea may improve insulin sensitivity and reduce systemic inflammation. Cardiovascular risks—including hypertension, arrhythmias and stroke—are significantly higher in untreated OSA patients [5] [14]. OSA is linked to high blood pressure, blood pressure fluctuations, heart failure, congestive heart failure, coronary artery disease. Repeated drops in blood oxygen levels during apnea episodes contribute to cardiovascular problems and increased risk of adverse health outcomes.
OSA management is moving beyond traditional diagnostics and CPAP therapy. Today's clinicians are using home-based testing, telehealth, AI tools and phenotype-driven care to tailor treatments and improve outcomes. While CPAP is still central, patient engagement, innovation and multidisciplinary care are shaping the future of sleep medicine.
[1] Gottlieb, D. J., & Punjabi, N. M. (2020). Diagnosis and Management of Obstructive Sleep Apnea: A Review. JAMA, 323(14), 1389–1400. https://doi.org/10.1001/jama.2020.3514
[2] Spicuzza, L., Attinà, A., Bignamini, E., Cilla, M., De Bortoli, J., Di Michele, L., Foresi, A., Malorgio, E., Marino, L., Rocca, A., Toraldo, D. M., & Sanna, A. (2025). Telemedicine in the Management of Patients with Obstructive Sleep Apnea: Evidence from the Literature and Practical Issues. A Consensus Document from the Task Force for Telemedicine in Respiratory Diseases, Part of the Italian Society of Telemedicine. Telemedicine journal and e-health : the official journal of the American Telemedicine Association, 10.1089/tmj.2024.0573. Advance online publication. https://doi.org/10.1089/tmj.2024.0573
[3] Maher, L. L. M., & Coke, L. A. (2021). Diagnosis and treatment of obstructive sleep apnea and its impact on cardiovascular disease. Journal of the American Association of Nurse Practitioners, 34(2), 389–396. https://doi.org/10.1097/JXX.0000000000000632
[4] Semelka, M., Wilson, J., & Floyd, R. (2016). Diagnosis and Treatment of Obstructive Sleep Apnea in Adults. American family physician, 94(5), 355–360. https://pubmed.ncbi.nlm.nih.gov/27583421/
[5] White D. P. (2006). Sleep apnea. Proceedings of the American Thoracic Society, 3(1), 124–128. https://doi.org/10.1513/pats.200510-116JH
[6] Hynes, D., & Mansfield, D. (2024). Diagnosis and management of obstructive sleep apnoea in adults. Australian prescriber, 47(2), 52–56. https://doi.org/10.18773/austprescr.2024.010
[7] Labarca, G., Henríquez-Beltrán, M., & Solomons, D. (2025). Precision Medicine to Guide Obstructive Sleep Apnea Treatment Beyond the Continuous Positive Airway Pressure. Seminars in respiratory and critical care medicine, 10.1055/a-2591-5502. Advance online publication. https://doi.org/10.1055/a-2591-5502
[8] Goyal, M., & Johnson, J. (2017). Obstructive Sleep Apnea Diagnosis and Management. Missouri medicine, 114(2), 120–124. https://pubmed.ncbi.nlm.nih.gov/30228558/
[9] Yeşildağ, M., & Duksal, F. (2025). Comorbidities and anthropometric parameters in obstructive sleep apnea syndrome: a phenotype-based study. Clinical and experimental hypertension (New York, N.Y. : 1993), 47(1), 2512136. https://doi.org/10.1080/10641963.2025.2512136
[10] Araujo, M. L. D., Winger, T., Ghosn, S., Saab, C., Srivastava, J., Kazaglis, L., Mathur, P., & Mehra, R. (2025). Status and opportunities of machine learning applications in obstructive sleep apnea: A narrative review. Computational and structural biotechnology journal, 28, 167–174. https://doi.org/10.1016/j.csbj.2025.04.033
[11] Light, M., McCowen, K., Malhotra, A., & Mesarwi, O. A. (2018). Sleep apnea, metabolic disease, and the cutting edge of therapy. Metabolism: clinical and experimental, 84, 94–98. https://doi.org/10.1016/j.metabol.2017.09.004
[12] De Luca Canto, G., Pachêco-Pereira, C., Aydinoz, S., Major, P. W., Flores-Mir, C., & Gozal, D. (2015). Diagnostic capability of biological markers in assessment of obstructive sleep apnea: a systematic review and meta-analysis. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 11(1), 27–36. https://doi.org/10.5664/jcsm.4358
[13] Xiao, Z., Li, X., Zhou, L., Long, X., Tian, L., & Li, W. (2025). Drug-Induced Sleep Endoscopy and Its Recent Clinical Applications in Combination with Other Procedures in Children: A Narrative Review. Nature and science of sleep, 17, 1067–1077. https://doi.org/10.2147/NSS.S498360
[14] Kang, H., Chow, C., Lobo, J., Logan, J., Bonner, H., Cho, Y., Liu, X., Mazimba, S., & Kwon, Y. (2025). Positional obstructive sleep apnea and cardiovascular outcomes. Sleep & breathing = Schlaf & Atmung, 29(3), 190. https://doi.org/10.1007/s11325-025-03342-y
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Mosanna Therapeutics gains $80m to advance OSA nasal spray
Mosanna Therapeutics has secured $80m in a Series A funding round to advance a new nighttime nasal spray for obstructive sleep apnoea (OSA). The company is developing MOS118, an easy-to-use nasal spray for OSA that helps restore the body's natural airway control. Pivotal bioVenture Partners and EQT Life Sciences headed the financing. Co-lead investors were Forbion, Broadview Ventures and Norwest. Returning investors for this round were Supermoon Capital and High-Tech Gründerfonds (HTGF), and founding investor Forty51 Ventures. EQT Life Sciences managing director Daniela Begolo stated: "What sets Mosanna apart is its fundamentally different approach to sleep apnea, treating it as a neurological and muscular dysfunction rather than a purely mechanical issue. "MOS118 is the first therapy with the potential to restore the body's natural airway reflex with the simplicity of a nasal spray. MOS118 has the potential to dramatically improve adherence and outcomes in a patient population that has long been underserved." OSA affects around one billion individuals worldwide and is associated with significant health risks such as hypertension and cardiovascular disease. Current treatments often involve mechanical solutions that can be uncomfortable for patients. Mosanna's MOS118 nasal spray aims to address these issues by targeting upper airway muscles to maintain airway patency during sleep. The new funding will support the spray through its Phase II development while also expanding Mosanna's product pipeline. Mosanna has appointed Dr David Weber as president and CEO to guide the next stage of the company's growth. Pivotal bioVenture partner Jeni Lee stated: "With his deep expertise in biotech innovation and patient-centric therapies, Dr Weber was the ideal choice to lead Mosanna into the next chapter. "We look forward to partnering with him and the Mosanna team to deliver on the promise of this life-changing sleep apnoea treatment." "Mosanna Therapeutics gains $80m to advance OSA nasal spray" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
19 hours ago
- Yahoo
Somnics Health Launches iNAP Essentials: Making Innovative OSA Therapy Accessible for $58/Month
REDWOOD CITY, Calif., June 09, 2025--(BUSINESS WIRE)--Somnics Health, a pioneer in next-generation sleep apnea solutions, announces the launch of iNAP Essentials, a breakthrough program giving patients access to iNAP Sleep Therapy for just $58/month over 24 months. This new initiative removes one of the biggest barriers to treatment—cost—and expands access to comfortable, mask-free therapy for patients with Obstructive Sleep Apnea (OSA). More than 50 million Americans suffer from OSA, yet 80% remain untreated, and many who start CPAP therapy abandon it due to discomfort. The iNAP system offers a new path forward. "The OSA treatment landscape is no longer CPAP-only. iNAP is effective, comfortable, and discreet—and now, more affordable than ever," said Olivier Lauzeral, General Manager of Somnics Health. "With iNAP Essentials, we're removing the affordability hurdle." A Smarter, Simpler Solution iNAP is an FDA-cleared, clinically validated therapy that uses gentle negative pressure to keep the airway open during sleep—without forcing air through a mask. It works by creating a light vacuum in the oral cavity, shifting soft tissues forward and preventing obstruction. Key benefits include: No mask, no noise, no forced air Compact and travel-friendly Rechargeable battery lasting up to 5 nights Patients appreciate the freedom and discretion the iNAP system offers, particularly for travel and daily life. "Adherence is one of iNAP's biggest strengths," added Lauzeral. "When therapy fits into your life instead of disrupting it, patients stay with it—and that's how we win against OSA." What's Included in iNAP Essentials For $58/month for 24 months, iNAP Essentials includes: A full iNAP Starter Kit 3 months of supplies (mouthpiece, tubing) Free nationwide shipping Personalized onboarding with a trained iNAP Sleep Coach Access to the iNAP Sleep App for tracking progress and sharing data with providers After the initial supply period, patients can purchase refills as needed from Somnics' online store—offering flexibility without hidden fees or long-term commitments. "We built this program with transparency and simplicity at its core," said Lauzeral. "It's everything you need to start treatment—nothing you don't." Addressing a Changing Market While CPAP has long dominated the OSA space, patient dissatisfaction is driving demand for alternatives like oral appliances, positional therapy, and implantable devices. Many of these, however, are costly, invasive, or hard to access. iNAP stands out as non-invasive, portable, and now financially accessible. Clinical studies show iNAP can significantly reduce AHI, with outcomes on par with CPAP—but with higher comfort and adherence. More Ways to Access iNAP For patients who prefer to own their device upfront, Somnics has partnered with Affirm® to offer interest-free installment plans. "Some patients want to purchase the device outright. With Affirm, they can do that without financial strain," said Lauzeral. Provider-Guided, Patient-Focused iNAP is available by prescription only, ensuring medical oversight from a sleep specialist. Adoption is growing across VA hospitals, sleep centers, and DME providers. "Physicians are seeing the value of iNAP in improving adherence and patient satisfaction," Lauzeral emphasized. "When patients feel empowered, they stay engaged—and that's the future of sleep medicine." Advancing Health Equity Untreated sleep apnea increases the risk of heart disease, stroke, diabetes, and cognitive decline. Somnics Health sees iNAP Essentials not just as a product offering—but as a public health solution. "This isn't just about access—it's about fairness," said Lauzeral. "Sleep apnea is a serious condition, and we believe everyone deserves a shot at better health." About Somnics Health Somnics Health is a medical device company focused on advancing patient-centric solutions for sleep-disordered breathing. Its flagship product, iNAP Sleep Therapy, helps patients treat OSA without the discomfort of traditional therapies. With offices in California and Taiwan, Somnics continues to lead in innovation, education, and patient adherence. Learn More: View source version on Contacts Press Contact: Olivier Lauzeral – olivier@ Follow us on: LinkedIn | Facebook | YouTube Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Los Angeles Times
21 hours ago
- Los Angeles Times
How Obstructive Sleep Apnea Treatment Is Evolving
Obstructive Sleep Apnea (OSA) is a common and serious sleep disorder characterized by repeated episodes of upper airway obstruction during sleep. Symptoms of OSA include loud snoring, excessive daytime sleepiness and observed episodes where you stop breathing during sleep. Understanding your individual risk factors is key to diagnosis and management. OSA affects 1 in 5 adults and contributes to cardiovascular disease, metabolic dysfunction and poor quality of life. Untreated OSA is associated with serious health problems like cardiovascular disease and can reduce life expectancy. With the growth of precision medicine, digital health and behavioral interventions OSA care is moving from one size fits all to personalized approaches. Polysomnography (PSG) is the gold standard for diagnosing OSA especially in complex or high risk cases [4] [6]. A sleep study is done in a sleep center and reviewed by a sleep specialist to ensure accurate diagnosis. As part of the assessment a healthcare provider will review your medical history and bedtime routine to evaluate risk factors and sleep patterns. The diagnosis process involves identifying symptoms of obstructive sleep such as loud snoring, daytime sleepiness and witnessed apneas. There are different types of sleep apnea including obstructive sleep apnea and central sleep apnea. Obstructive apneas and breathing pauses are key findings during a sleep study while central sleep apnea is when the brain fails to send signals to breathing muscles resulting in central sleep disruptions. Something like this is different from other sleep-related issues such as narcolepsy and insomnia. But recent updates support the growing role of home sleep apnea testing (HSAT), especially for patients with high pretest probability and fewer comorbidities [1] [3]. These tests get obstructive sleep apnea diagnosed. Portable devices now offer reliable data while improving access and reducing costs. The 2015 systematic review also highlighted the emerging value of biomarkers—like IL-6 and kallikrein-1—as potential tools for assessing OSA severity [12]. Continuous Positive Airway Pressure (CPAP) is the foundation of OSA treatment especially in moderate to severe cases. Many studies have shown its effectiveness in reducing apnea events, improving sleep quality and lowering cardiovascular risk [1] [4] [5]. CPAP and other interventions keep the airway open and get sleep apnea treated. But adherence is a major challenge. Alternatives like oral appliances, positional therapy and upper airway surgery are effective in milder cases or when CPAP is poorly tolerated [3] [6] [8]. Surgery may be necessary for patients with severe symptoms or when other therapies fail. Severe sleep apnea and severe OSA may require more aggressive or combination therapies. Lifestyle changes like weight loss, exercise and alcohol/tobacco cessation are foundational interventions that should be part of any treatment plan [1] [3]. These lifestyle changes are key to managing mild sleep apnea and mild obstructive sleep apnea. A comprehensive approach is often needed to get obstructive sleep apnea treated and to treat OSA. Not all OSA cases are the same. Advances in phenotyping—the classification of patients by symptom clusters, anatomy and comorbidities—are shaping precision medicine approaches [7] [9]. This has led to new algorithms for selecting ideal therapies based on individual traits rather than a one size fits all CPAP prescription. A 2025 phenotype-based study showed how different comorbidity profiles may predict which patients need early referral and treatment escalation [9]. The COVID-19 pandemic accelerated the adoption of telemedicine and sleep medicine was no exception. Virtual consultations, remote device monitoring and app-based interventions are being integrated into care. While current evidence is limited to consensus reports, early data suggests improved adherence and symptom tracking when digital tools are used [2]. Artificial intelligence (AI) and machine learning (ML) are being explored to streamline diagnosis, predict treatment outcomes and detect high-risk phenotypes [10]. A 2025 review noted the need for standardized datasets and validation models before widespread clinical use but the future looks promising. Positional OSA, where apnea events occur primarily when lying on the back, has different cardiovascular outcomes and may respond to targeted interventions like positional therapy [14]. Airway obstruction in positional OSA occurs when the muscles in the back of the throat relax and the airway narrows and collapses. Meanwhile drug-induced sleep endoscopy (DISE) in pediatric populations is gaining popularity as a tool to visualize dynamic airway collapse and guide surgical decision making [13]. Visualization during DISE often shows collapse at the level of the soft palate which guides surgical decisions. OSA's role in metabolic disease, including type 2 diabetes, dyslipidemia, metabolic syndrome and diabetes mellitus is being uncovered [11]. Treating sleep apnea may improve insulin sensitivity and reduce systemic inflammation. Cardiovascular risks—including hypertension, arrhythmias and stroke—are significantly higher in untreated OSA patients [5] [14]. OSA is linked to high blood pressure, blood pressure fluctuations, heart failure, congestive heart failure, coronary artery disease. Repeated drops in blood oxygen levels during apnea episodes contribute to cardiovascular problems and increased risk of adverse health outcomes. OSA management is moving beyond traditional diagnostics and CPAP therapy. Today's clinicians are using home-based testing, telehealth, AI tools and phenotype-driven care to tailor treatments and improve outcomes. While CPAP is still central, patient engagement, innovation and multidisciplinary care are shaping the future of sleep medicine. [1] Gottlieb, D. J., & Punjabi, N. M. (2020). Diagnosis and Management of Obstructive Sleep Apnea: A Review. JAMA, 323(14), 1389–1400. [2] Spicuzza, L., Attinà, A., Bignamini, E., Cilla, M., De Bortoli, J., Di Michele, L., Foresi, A., Malorgio, E., Marino, L., Rocca, A., Toraldo, D. M., & Sanna, A. (2025). Telemedicine in the Management of Patients with Obstructive Sleep Apnea: Evidence from the Literature and Practical Issues. A Consensus Document from the Task Force for Telemedicine in Respiratory Diseases, Part of the Italian Society of Telemedicine. Telemedicine journal and e-health : the official journal of the American Telemedicine Association, 10.1089/tmj.2024.0573. Advance online publication. [3] Maher, L. L. M., & Coke, L. A. (2021). Diagnosis and treatment of obstructive sleep apnea and its impact on cardiovascular disease. Journal of the American Association of Nurse Practitioners, 34(2), 389–396. [4] Semelka, M., Wilson, J., & Floyd, R. (2016). Diagnosis and Treatment of Obstructive Sleep Apnea in Adults. American family physician, 94(5), 355–360. [5] White D. P. (2006). Sleep apnea. Proceedings of the American Thoracic Society, 3(1), 124–128. [6] Hynes, D., & Mansfield, D. (2024). Diagnosis and management of obstructive sleep apnoea in adults. Australian prescriber, 47(2), 52–56. [7] Labarca, G., Henríquez-Beltrán, M., & Solomons, D. (2025). Precision Medicine to Guide Obstructive Sleep Apnea Treatment Beyond the Continuous Positive Airway Pressure. Seminars in respiratory and critical care medicine, 10.1055/a-2591-5502. Advance online publication. [8] Goyal, M., & Johnson, J. (2017). Obstructive Sleep Apnea Diagnosis and Management. Missouri medicine, 114(2), 120–124. [9] Yeşildağ, M., & Duksal, F. (2025). Comorbidities and anthropometric parameters in obstructive sleep apnea syndrome: a phenotype-based study. Clinical and experimental hypertension (New York, N.Y. : 1993), 47(1), 2512136. [10] Araujo, M. L. D., Winger, T., Ghosn, S., Saab, C., Srivastava, J., Kazaglis, L., Mathur, P., & Mehra, R. (2025). Status and opportunities of machine learning applications in obstructive sleep apnea: A narrative review. Computational and structural biotechnology journal, 28, 167–174. [11] Light, M., McCowen, K., Malhotra, A., & Mesarwi, O. A. (2018). Sleep apnea, metabolic disease, and the cutting edge of therapy. Metabolism: clinical and experimental, 84, 94–98. [12] De Luca Canto, G., Pachêco-Pereira, C., Aydinoz, S., Major, P. W., Flores-Mir, C., & Gozal, D. (2015). Diagnostic capability of biological markers in assessment of obstructive sleep apnea: a systematic review and meta-analysis. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 11(1), 27–36. [13] Xiao, Z., Li, X., Zhou, L., Long, X., Tian, L., & Li, W. (2025). Drug-Induced Sleep Endoscopy and Its Recent Clinical Applications in Combination with Other Procedures in Children: A Narrative Review. Nature and science of sleep, 17, 1067–1077. [14] Kang, H., Chow, C., Lobo, J., Logan, J., Bonner, H., Cho, Y., Liu, X., Mazimba, S., & Kwon, Y. (2025). Positional obstructive sleep apnea and cardiovascular outcomes. Sleep & breathing = Schlaf & Atmung, 29(3), 190.
